Bicycle Therapeutics plc (NASDAQ: BCYC) stock closed at 26.25 per share at the end of the most recent trading day (a 1.31% change compared to the prior day closing price) with a volume of 276.65K shares and market capitalization of 779.00M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 81 people. Bicycle Therapeutics plc CEO is Kevin Lee.

The one-year performance of Bicycle Therapeutics plc stock is -10.44%, while year-to-date (YTD) performance is -56.88%. BCYC stock has a five-year performance of %. Its 52-week range is between 12.08 and 62.075, which gives BCYC stock a 52-week price range ratio of 28.34%

Bicycle Therapeutics plc currently has a PE ratio of -8.60, a price-to-book (PB) ratio of 2.47, a price-to-sale (PS) ratio of 47.05, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.94%, a ROC of -31.95% and a ROE of -38.42%. The company’s profit margin is -%, its EBITDA margin is -514.10%, and its revenue ttm is $16.34 Million , which makes it $0.55 revenue per share.

Of the last four earnings reports from Bicycle Therapeutics plc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.82 for the next earnings report. Bicycle Therapeutics plc’s next earnings report date is -.

The consensus rating of Wall Street analysts for Bicycle Therapeutics plc is Strong Buy (1.42), with a target price of $63.5, which is +141.91% compared to the current price. The earnings rating for Bicycle Therapeutics plc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bicycle Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bicycle Therapeutics plc has a Buy technical analysis rating based on Technical Indicators (ADX : 10.87, ATR14 : 1.96, CCI20 : 80.56, Chaikin Money Flow : 0.17, MACD : 2.05, Money Flow Index : 57.46, ROC : 7.80, RSI : 60.60, STOCH (14,3) : 64.19, STOCH RSI : 0.07, UO : 55.35, Williams %R : -35.81), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bicycle Therapeutics plc in the last 12-months were: Alistair Milnes (Option Excercise at a value of $103 719), Dominic Smethurst (Option Excercise at a value of $111 300), Kevin Lee (Option Excercise at a value of $491 652), Kevin Lee (Sold 55 118 shares of value $2 250 189 ), Nicholas Keen (Option Excercise at a value of $216 678), Nicholas Keen (Sold 18 321 shares of value $774 682 ), Pierre Legault (Option Excercise at a value of $1 269 686), Pierre Legault (Sold 150 000 shares of value $8 653 889 )